Object. Delayed ischemic deficits (DIDs), a major source of disability following aneurysmal subarachnoid hemorrhage (aSAH), are usually associated with severe cerebral vasospasm and impaired autoregulation. Systemic erythropoietin (EPO) therapy has been demonstrated to have neuroprotective properties acting via EPO receptors on cerebrovascular endothelia and ischemic neurons. In this trial, the authors explored the potential neuroprotective effects of acute EPO therapy following aSAH.
D
elayeD ischemic deficits, a major source of disability and unfavorable outcome following aSAH, are usually associated with severe cerebral vasospasm and impaired autoregulation. 26 Existing evidence suggests that SAH-induced perivascular inflammation attenuates activities of eNOS. 9 Furthermore, the oxyhemoglobin released from subarachnoid blood enhances production of superoxides in cerebral vessels, causing depletion of NO with concomitantly excessive production of lipid oxygen free radicals, which consequently cause impaired cerebral autoregulation and vasospasm. 7 Since vasospasm-related cerebral infarcts often manifest a few days after the initial bleed, aSAH is a useful model to explore prophylactic therapy for evolving cerebral ischemia.
Cerebral autoregulation, an intrinsic protective mechanism against ischemia, can be measured with the THRT on TCD ultrasonography. 13 During this test, a sharp fall in flow velocities of the MCA is induced by manual compresAcute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial sion on the carotid artery. Within a few seconds, compensatory cerebral vasodilatation reflects intact autoregulation. On releasing the compression a quantifiable transient hyperemic response is seen. Impaired THRT often accompanies vasospasm, and can be used to predict onsets of DIDs and unfavorable outcome following aSAH.
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Systemic EPO therapy has been demonstrated to have neuroprotective properties acting via EPO receptors on cerebrovascular endothelia and ischemic neurons. 5 Potential benefits of systemic EPO therapy have been suggested in patients with acute stroke, 11 and mechanisms involve ischemic preconditioning, antiapoptosis, neurogenesis, and angiogenesis in ischemic penumbra. 5, 23 Systemic EPO also interacts with cerebrovascular endothelial EPO receptors, 31 which subsequently activates protein kinase B and phosphorylation of eNOS, increases nitrous oxide production, and elevates cyclic 3',5'-guanosine monophosphate levels in cerebral artery. 29 Indeed, experimental models of SAH have demonstrated that acute systemic EPO therapy reverses impaired autoregulation, 31 reduces vasospasm and DIDs, and improves neurological outcome. 14 These positive effects of EPO on cerebral vasospasm and autoregulation have encouraged us to design a Phase II, proof-of-concept trial to test the hypothesis that acute systemic EPO therapy in patients following aSAH can reduce cerebral vasospasm and shorten impaired autoregulation as primary end points, which subsequently decrease DID and improve clinical outcome as secondary end points.
Methods

Patient Population
The trial was approved by Cambridge Local Research Ethics Committee (04/Q0108/87) and Medicines and Healthcare Products Regulatory Agency (EudraCT 2004-001141-15), registered with ClinicalTrials.org (NCT00140010), and conducted at Addenbrooke's Hospital (a tertiary referral center in East Anglia, UK, covering a population of > 2.4 million). Because aSAH is rare in patients younger than 18 years of age, only adult patients (> 18 years) were approached. Baseline demographic data were collected together with medical history, WFNS SAH grade, 8 Fisher grade on CT, 12 and factors that might have adversely affected outcome (Table 1) . Exclusion criteria were nonaneurysmal SAH, uncontrolled hypertension (systolic blood pressure > 220 mm Hg) and history of malignancy or thromboembolism).
Study Design and Treatment
After admission, clinical management included oral nimodipine (Nimotop, Bayer, Berks) 60 mg/4 hours and intravenous fluid supplementation (3 L/day) with crystalloids (0.9% saline) and/or synthetic colloids (4% succinylated gelatin [Gelofusine, Braun], or 6% pentastarch [HAES-steril, Fresenius Kabi]). Blood samples for full cell count, reticulocytes, and biochemistry were taken at admission and repeated every 3 days. For symptomatic vasospasm, patients received induced triple-H therapy 18 but no endovascular angioplasty. Transfusions with packed erythrocytes were given for hemoglobin < 80 g/L.
Three identical vials containing either 6 ml of epoetin-beta 30,000 U (NeoRecormon, Roche Products) in 0.9% saline or 0.9% saline only were grouped as 1 set/patient (total 80 sets, EPO/placebo 1:1) and randomized independently by the Ipswich Pharmacy Manufacture Unit. Randomization was performed according to a computergenerated randomization list. Each set was sequentially numbered and assigned to a patient with the content only known by the Ipswich Pharmacy. Informed written consent was obtained, and trial medications were given by nursing staff as intravenous bolus injections for 15 minutes on the day of recruitment and then every 48 hours for a total of 3 doses (90,000 U). Both patients and investigators were blinded to the treatment allocation, and the randomization code was not broken until the last recruited patient was assessed at 6 months.
Transcranial Doppler Examination
Daily TCD ultrasonography (DWL Multi-Dop X 4) was performed at ~ 10 am for up to 14 days using a 2-MHz probe mounted on a purpose-designed head frame. Concomitant MABP was measured with the cuff method or intraarterial catheter. Mean flow velocity in MCA was captured (50-60 mm depth) and recorded via in-house designed BioSan together with digitalized MABP signals (Data Translation). 29 Vasospasm was defined according to 3 TCD ultrasonography criteria: After carotid atheromas were excluded by 2D ultrasonography and a 10-second baseline recording, manual compression on the carotid artery for 5-7 seconds was performed. Criteria for acceptable THRT included a sudden decrease in the mean flow velocity at the onset of compression, stable flow velocity during the compression, and a minimum of 30% decrease in mean flow velocity without MABP instability. The transient hyperemic response ratio was calculated as FV systolic (hyperemia) / FVsystolic (baseline) and defined as normal (≥ l.10) or impaired (< 1.10) autoregulation, where FV is flow velocity.
13,30
Surveillance and Follow-Up
Although EPO has effects of erythropoiesis and thrombopoiesis, associated adverse events have not been observed in short-term treatment in patients who have suffered stroke.
11 However, a safety committee (chaired by H.K.R.) was set up to review the mortality rate when the first 20 patients finished the trial. A predefined stopping rule was defined as a higher mortality associated with EPO therapy.
Adverse clinical events, including deaths, uncontrollable systemic hypertension, or thromboembolism, were immediately reported to the trial manager of Addenbrooke's Hospital, the Medicines and Healthcare Products Regulatory Agency, Roche Products UK, and the study statistician (H.K.R.). A DID was defined as new focal neurological deficit or reduction in the Glasgow Coma Scale ≥ 2 points 27 and were further categorized as vasospasm related if the criteria for vasospasm on TCD ultrasound were met. Other causes of neurological deteriora-tion were excluded by repeated CT scanning, metabolic screening, and electroencephalographic monitoring.
Outcomes at discharge and at 6 months were assessed by an independent neurosurgeon (P.J.H.) according to the mRS 3 and the GOS 17 as favorable (mRS Score 0-3, or GOS score of good recovery/moderate disability) or unfavorable (mRS Score 4-6, or GOS score of severe disability/vegetative/death). For survivors at discharge, the deficits were categorized according to the NIHSS 4, 6 as mild (Score 0-5), moderate (Score 6-20), or severe (score > 20).
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The primary end points of the study were: 1) incidence, duration, and severity of vasospasm on TCD ultrasound; and 2) duration of impaired autoregulation on THRT. The secondary end points were: 1) the incidence of DIDs; and 2) outcome at discharge and at 6 months.
Statistical Analysis
Previous observations in our unit indicated that vasospasm on TCD ultrasonography occurred in 64% of patients. 20, 34 To demonstrate a 50% reduction in incidence with a power of 80% and a significance level of 5%, examination of 72 patients was required. Assuming 90% follow-up, 80 patients were recruited.
Analyses were performed as intention-to-treat using STATA Intercooled 8.0 for Windows. When applicable data are presented as the mean ± SD with 95% CIs. All p values were 2 sided and p < 0.05 was considered significant. Randomization characteristics, incidence of vasospasm, and secondary end points were compared using the chi-square or Fisher exact test (when any number of the cell was < 5), except for age, where the t-test was used. Durations of vasospasm and impaired autoregulation were compared using the Mann-Whitney U-test and separately according to the side of ruptured aneurysm. Laboratory data were examined using the ANOVA for repeated measurements. When it showed significance within individuals, tables of Dunnett correction were applied to identify significant changes over time. 10 Multivariate logistic regression for unfavorable GOS outcome was built by backward stepwise regression using the log likelihood test with a critical p < 0.05.
Results
Patient Population
Between April 2005 and April 2006, 94 patients with aSAH were approached about taking part in the trial: 8 refused to participate, 4 were excluded for participating in other trials, and 2 withdrew from medical care because of poor conditions, leaving 80 individuals (age range 24-82 years) for recruitment and randomization. An interim analysis on mortality of the first 20 patients showed no difference between the trial arms, and therefore the trial was continued until all the 80 patients were recruited.
Trial medications were given within 1.7 ± 1.5 days (95% CI 1.3-2.0 days) of SAH. Forty-two patients completed 14-day TCD examinations, whereas 9 died during hospitalization and 29 were well enough to be discharged early, none of whom were readmitted with symptomatic vasospasm. The end points observed for all 80 patients, including death, were drawn into the final analyses (Fig. 1) .
Randomization Characteristics
Randomization characteristics were balanced between the trial groups, except for age, with patients in the EPO group being older (p = 0.034) ( Table 1) .
Primary End Points
No differences in overall incidence or duration of vasospasm were found between the trial groups ( Table 2) . For severe vasospasm, the incidence and duration were significantly reduced by EPO from 27.5 to 7.5% (p = 0.037) and by 1.0 day (p = 0.028), respectively, particularly on the ipsilateral side to the culprit aneurysm.
There was no difference in baseline transient hyperemic response ratio between the trial groups. Subsequent measurements showed reduced ipsilateral transient hyperemic response ratio or deterioration in autoregulation in the placebo group between Days 7 and 9 (−0.09 ± 0.19, 95% CI −0.01 to −0.17, p = 0.027). No significant changes in transient hyperemic response ratio were seen on the contralateral side or in the EPO group. Duration of impaired autoregulation on the ipsilateral side was shortened by EPO by 3.2 days (p < 0.001) but not on the contralateral side.
Secondary End Points
Nineteen patients (16 placebo and 3 EPO) with DIDs had new infarcts on CT, including 14 with new focal neurological deficits and 5 with reductions in GCS score of > 2 points. Thirteen patients with DIDs (10 placebo and 3 EPO) had infarcts corresponding to the territory of vasospasm on TCD ultrasonography. The other 6 patients had infarcts corresponding to the vascular territory associated with TCD velocities > 1.2 m/second and Lindegaard ratio > 3 but without an acute increment of flow velocity > 0.5 m/sec/24 hours. The incidence of DIDs was reduced by EPO from 40.0 to 7.5% (p = 0.001) ( Table 3) .
No systemic thromboembolism or uncontrolled hypertension was observed. Other adverse events, including ventriculitis (8 cases), immediate postoperative deficits (18 cases), sepsis (30 cases), and early death (9 cases), were not different between the trial groups. The 9 deaths during hospitalization included 5 patients who suffered rehemorrhage (3 placebo, 2 EPO), 2 with immediate postoperative infarcts (1 placebo, 1 EPO), and 2 with vasospasm-related infarcts (1 placebo, 1 EPO).
Although there was no difference in overall outcome at discharge, there was a trend toward more EPO-treated patients achieving favorable outcome (favorable mRS score p = 0.10, favorable GOS score p = 0.039). Among the 71 survivors, the EPO group had a lower NIHSS score (median= 0.002), older age (OR 2.21/decade after 40 years, 95% CI 1.20-4.09/decade, p = 0.011), immediate postoperative deficits (OR 4.43, 95% CI 1.20-16.4, p = 0.026), and sepsis (OR 3.34, 95% CI 0.94-11.86, p = 0.062) as variables promoting unfavorable GOS scores at 6 months, whereas EPO was associated with a 73% reduction (OR 0.27, 95% CI 0.07-1.04, p = 0.057).
Laboratory Data
No differences in baseline laboratory data were found between the trial groups. In the placebo group, the absolute reticulocyte count remained within the normal range (10-100 × 10 9 /L) (Fig. 2) . In the EPO group, the absolute reticulocyte count was above the normal range between /L, p < 0.001). However, no significant intergroup differences in baseline and subsequent hematocrits were seen.
Effects On Blood Pressure
No differences in baseline and subsequent measurements of MABP were found between the trial groups (Fig. 3) . Compared with the baseline, the placebo group had significant increments in MABP from Day 4 to Day 12 with a maximal increment during Days 7 to 9 (+ 7.2 mm Hg, 95% CI 3.3-11.0 mm Hg, p < 0.001), which were most likely to be associated with the triple-H therapy for severe vasospasm (p = 0.003, ANOVA). In the EPO group, changes in MABP from the baseline were not significant.
Effects on Transfusions and Fluid Therapy
Compared with the placebo group, fewer patients taking EPO had transfusions with packed erythrocytes (12 placebo vs 4 EPO, Fisher exact p = 0.048). Neither the quantity for each transfused patient (0.81 ± 0.43 L) nor the interval between SAH and the first transfusion (9.9 ± 7.5 days) showed any intergroup differences.
All patients received intravenous crystalloids on admission. Compared with the placebo group, EPO-treated patients seemed to have a shorter duration (10.9 ± 7.5 vs 8.0 ± 5.7 days, p = 0.06) and smaller quantity (20.9 ± 15.8 vs 15.3 ± 11.7 L, p = 0.07) of intravenous crystalloid therapy.
Fifty-nine patients received intravenous synthetic colloids. No differences were seen in the number of patients, the interval between SAH and the first dose (3.3 ± 3.6 days), the duration (3.5 ± 4.0 days), and the quantity of synthetic colloids (3.5 ± 4.9 L) between the 2 groups.
Discussion
Although preliminary results from the study did not demonstrate that EPO had significant effects on overall incidence of cerebral vasospasm, the benefits can be observed on severe vasospasm and DIDs with cerebral infarcts. The 3 outcome measures at discharge (GOS, mRS, and NIHSS scores) exhibited a similar tendency in clinical improvement, which seemed to dissipate by 6 months; this a finding is in line with other trials treating acute brain injury in which authors found early benefits were diluted in long-term follow-up. 24, 35 Even so, multivariate analyses identified a trend toward positive effects from EPO in long term, suggesting the neuroprotection was durable.
It is recognized that TCD flow velocity alone is not an adequate surrogate for angiographically detected vasospasm, particularly when autoregulation is impaired.
1,2
Hence, 3 TCD criteria for estimating the occurrence and severity of vasospasm, and concomitant assessment of cerebral hemodynamics using the THRT, were adopted in this study, both of which have proven predictive in the occurrence of DIDs and unfavorable outcome following aSAH.
20,28
The imbalance in age influenced both the primary and secondary end points. Patients in whom TCD ultrasound demonstrated vasospasm were generally younger (mean age 52.1 ± 10.0 vs 61.2 ± 14.7 years, p = 0.002). Cerebral atherosclerosis, a condition associated with reduced cerebrovascular reactivity, is commonly seen in the elderly who are also more likely to suffer preexisting medical conditions, sepsis, or cognitive dysfunction. 21 Thus, their recovery may not proceed at the same rate and to the same extent as younger patients. 16, 21, 25 Such factors could dilute any potential benefits of EPO in older patients.
Mechanisms of neurovascular protection by EPO may be generic and multifactorial. A similar dose used by Springborg et al. 32 in patients with aSAH has shown that (5) the concentration of EPO in CSF has increased significantly after intravenous administration, but it is only 0.2% of that found in serum, suggesting the neuroprotection may involve cerebrovascular effects associated with an early activation of endothelial EPO receptor 31 and stimulation of eNOS, 29 particularly on the side ipsilateral to the culprit aneurysm with maximum SAH-induced inflammation.
9 In addition to ischemic preconditioning, increased cerebral blood flow to the ischemic penumbra resulting from improved survival of vascular endothelia and angiogenesis, and enhanced neural plasticity may have reduced cerebral infarcts.
37 The 4 deaths due to malignant brain edema seen equally in each trial groups (2 vasospasm-related infarcts and 2 immediately postoperative infarcts) are unlikely to have been exacerbated by the study medication.
Issues of optimized dosage and frequency were not addressed in this trial. The dose was pragmatically fixed as the one known for both preclinical and clinical efficacy against cerebral ischemia.
5,11 The minimum effective dose and maximum duration for neuroprotection in animals have been reported to be 450 IU/kg and 48 hours, respectively, 5 which are in keeping with the dose and frequency used in this study. In vitro studies have demonstrated an overlap between the genetic programs of hematopoietic and neural stem cells, 33 and it was noteworthy that EPOtreated patients with an unfavorable outcome had smaller increases in the absolute reticulocyte count (89.3 ± 35.1 vs 140.4 ± 41.9 × 10 9 /L on Day 6, p < 0.001), and therefore this implies that the EPO-related enhanced hematopoiesis correlates with the neuroprotection, which may not have been fully exploited in some patients.
The higher reticulocyte count documented after EPO therapy was not reflected by a higher hematocrit or elevated MABP. The lack of overall difference in hematocrit levels between the trial groups may derive from the more frequent transfusions in the placebo group, suggesting that enhanced oxygen delivery by elevating the hematocrit level may not be the mechanism for the clinical benefits of EPO. Likewise, the elevated MABP, a common effect observed during EPO therapy in patients with endstage renal disease, 36 was not observed in the EPO group. Instead, it was more frequently observed in patients receiving the placebo, who were more likely to undergo the triple-H therapy for symptomatic vasospasm. The more increments of MABP in the placebo group could be a potential confounding factor and dilute any potential differences in secondary end points.
In a similar study conducted by Springborg et al.,
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EPO-alpha 500 IU/kg/day was delivered intravenously within 48 hours of SAH and 2 further doses at 24 and 48 hours were used. Their primary end point was the 6-month GOS score, while the secondary end points were brain physiological and biochemical parameters, including vasospasm on TCD ultrasonography, symptomatic vasospasm, cerebral metabolism, jugular venous oximetry, markers of brain damage, integrity of blood-brain barrier, and cere- bral infarcts on CT or MR imaging. They defined vasospasm according to a single criterion (flow velocity > 1.2 m/ second on TCD ultrasound, but Lindegaard ratio > 3 was not required). Because of slow recruitment, this study was terminated prematurely, and data in only 25-54 of the 73 recruited patients were analyzed, depending on the end points. Their results showed there were no differences in any of the end points and were thought to be caused by an * On the mRS = 1 no disability, 2 = slight disability, 3 = moderately disability, 4 = moderately severe disability, unable to walk without assistance, 5 = severe disability, bedridden, and 6 = death. † On the NIHSS there are a total of 42 points, where lower scores indicate less disability.
imbalance in WFNS score between the trial groups, where more patients in the EPO group had SAH of Grade V. Although Springborg et al. 32 found no significant differences in TCD-measured vasospasm based on a single criterion, the maximum flow velocity and the duration of flow velocity > 1.2 m/second (p = 0.20) seemed to be reduced in the EPO group, implying a tendency of decreased severity in vasospasm by EPO. Both Springborg et al. and the current study found no differences in 6-month outcome and hematocrit, but in the former's study the MABP was higher in the EPO group, probably because of more resuscitations for poor-grade patients. Therefore, although the 2 studies seem similar, the disagreement in results may be caused by differences in sample size, dosing intervals, end points chosen, definitions of end points, and timing of outcome measures (at discharge vs at 6 months). Indeed, Springborg et al. chose to terminate their study prematurely because of slow recruitment, but it might be suggested that had they continued, different findings would have been produced.
Several limitations of the present study include a small sample size, a single predefined dose of EPO, a single trial center, lack of timed CT scan data, and CT scans being performed only when clinical deterioration occurred (therefore introducing the possibility that asymptomatic cerebral infarcts may have been missed). Although it was not powered to detect differences in clinical outcome, the preliminary results suggested that acute systemic EPO therapy following aSAH seemed to accelerate early recovery by reducing adverse physiological and clinical events associated with delayed ischemic brain injury. These findings may justify further investigation on dose escalation of beneficial effects of EPO in the context of aSAH.
Conclusions
Because this preliminary study did not demonstrate reductions in the incidence of cerebral vasospasm with EPO therapy, the decreased clinical and physiological manifestations of delayed cerebral ischemia were therefore more likely to reflect neuroprotective and cerebrovascular effects of EPO. Future study of EPO therapy following aSAH is warranted. 
